01—Abstract
Summary
Summary of the 10-Q filed May 10, 2016. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a net sales increase of 24.1% to $55.5 milliona for the first quarter of 2016 compared to the prior year, driven by strong performance in both its TASER Weapons segment (up 19.5%) and its Axon segment (up 51.0%).
The Axon segment's growth was particularly notable, fueled by a significant increase in Evidence.com recurring revenues and strong bookings for new products, despite a temporary dip in recognized camera revenue due to the introduction of the Axon Body 2. While gross margins remained stable year-over-year at 66.5%b, operating expenses saw a substantial increase, primarily in Sales, General & Administrative (SG&A) and Research & Development (R&D) expenses. This increase is attributed to investments in expanding sales teams, product development for the growing Axon segment, and increased marketing efforts.
Consequently, net income decreased to $3.5 millionc ($0.06 per diluted share) from $7.2 million ($0.13 per diluted share) in the prior year's quarter, reflecting the higher operating expenses. The company also repurchased approximately $9.0 million of its common stock under a new $50 million repurchase program.
Financially, the company maintained a healthy liquidity position with $114.1 milliond in cash, cash equivalents, and investments at quarter-end, and no outstanding borrowings on its $10 million credit line. Despite the decrease in net income, the growth in net sales and bookings, particularly in the burgeoning Axon segment, indicates positive momentum for the company's strategic expansion into digital evidence management solutions.
02—Key points
Key Highlights
- Net sales increased by 24.1% to $55.5 million in Q1 2016 compared to Q1 2015, driven by growth in both TASER Weapons and Axon segments.
- The Axon segment showed robust growth, with net sales up 51.0% and Evidence.com recurring revenues increasing significantly.
- Gross margin remained stable at approximately 66.5% of net sales, indicating strong pricing power or cost management.
- Operating expenses, particularly SG&A and R&D, increased significantly (70.5% and 52.0% respectively), reflecting investments in sales expansion and product development.
- Net income decreased to $3.5 million ($0.06/share) from $7.2 million ($0.13/share) year-over-year due to higher operating expenses.
- The company launched a $50 million stock repurchase program and repurchased $9.0 million of common stock in Q1 2016.
- Strong bookings for Axon products and Evidence.com services ($52.1 million) indicate future revenue potential, a 126.9% increase from the prior year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2016, Axon Enterprise, Inc. kept $0.06.
- Revenue$55.5M100.0%
- Cost of revenue−$18.6M33.5%
- Gross profit$36.9M66.5%
- Operating costs−$31.8M57.2%
- Operating income$5.1M9.3%
- Interest, other & tax−$1.7M3.0%
- Net income$3.5M6.2%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2016filed May 10, 2016Financial Statements
Q1 FY2016 against Q1 FY2015
| Line item | Q1 FY2016Q1 FY2015 | Change |
|---|---|---|
| Revenue | $55.53M$44.76M | +24.1% |
| Cost of Revenue | $18.63M$14.89M | +25.1% |
| Gross Profit | $36.90M$29.87M | +23.6% |
| R&D Expenses | $6.93M$4.56M | +52.0% |
| SG&A Expenses | $24.83M$14.56M | +70.5% |
| Operating Expenses | $31.76M$19.12M | +66.1% |
| Operating Income | $5.14M$10.74M | −52.1% |
| Net Income | $3.46M$7.21M | −51.9% |
| EPS (Basic) | $0.06$0.14 | −57.1% |
| EPS (Diluted) | $0.06$0.13 | −53.8% |
| Shares Outstanding (Basic) | 53.69M53.17M | +1.0% |
| Shares Outstanding (Diluted) | 54.79M54.51M | +0.5% |
05—Questions
Frequently Asked Questions
What is the primary driver of the company's sales growth in the first quarter of 2016?
The primary driver of sales growth was a combination of strong performance in the TASER Weapons segment, particularly with large international orders, and significant growth in the Axon segment, led by increasing recurring revenues from Evidence.com and strong bookings for new Axon camera products.
Why did net income decrease despite the increase in net sales?
Net income decreased primarily due to a substantial increase in operating expenses. Sales, General & Administrative (SG&A) expenses rose by 70.5% and Research & Development (R&D) expenses increased by 52.0%, reflecting investments in expanding sales teams, developing new products for the Axon segment, and increased marketing activities.
What is the significance of the increase in 'bookings' for the Axon segment?
The significant increase in bookings for Axon products and Evidence.com services (up 126.9% to $52.1 million) is a key indicator of future revenue growth. It suggests strong market demand and customer commitment to the company's digital evidence management solutions and related hardware, even though the revenue is recognized over time.
What is the company's financial position and liquidity like at the end of Q1 2016?
The company maintained a strong liquidity position with $114.1 million in cash, cash equivalents, and investments. It had no outstanding borrowings on its $10 million revolving credit line, indicating a healthy balance sheet and capacity for future investments or operations.
06—Continue